Log in to save to my catalogue

Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali

Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9881676

Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In this phase 2 trial in Mali, an antimalarial monoclonal antibody (CIS43LS) at a dose of 40 mg per kilogram was approximately 88% effective at preventing
P. falciparum
infection as compared with placebo.

Alternative Titles

Full title

Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9881676

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9881676

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2206966

How to access this item